Article
Denver-Intravitreal bevacizumab (Avastin, Genentech) proved to be a successful treatment in a patient with neovascular glaucoma.
RhyGaze secures Series A financing of $86 million to further novel gene therapy
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Ocugen announces positive 2-year safety and efficacy update of Phase 1/2 OCU400 for treatment of retinitis pigmentosa
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery
4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME